Quest Diagnostics/$DGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Quest Diagnostics
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Ticker
$DGX
Sector
Primary listing
NYSE
Employees
50,500
Headquarters
Website
DGX Metrics
BasicAdvanced
$20B
21.52
$8.51
0.56
$3.15
1.75%
Price and volume
Market cap
$20B
Beta
0.56
52-week high
$197.55
52-week low
$148.70
Average daily volume
981K
Dividend rate
$3.15
Financial strength
Current ratio
1.128
Quick ratio
0.886
Long term debt to equity
77.345
Total debt to equity
86.524
Dividend payout ratio (TTM)
35.81%
Interest coverage (TTM)
5.61%
Profitability
EBITDA (TTM)
2,141
Gross margin (TTM)
33.45%
Net profit margin (TTM)
8.93%
Operating margin (TTM)
14.57%
Effective tax rate (TTM)
22.68%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
6.12%
Return on equity (TTM)
14.35%
Valuation
Price to earnings (TTM)
21.52
Price to revenue (TTM)
1.887
Price to book
2.8
Price to tangible book (TTM)
-6.15
Price to free cash flow (TTM)
14.699
Free cash flow yield (TTM)
6.80%
Free cash flow per share (TTM)
12.465
Dividend yield (TTM)
1.72%
Forward dividend yield
1.75%
Growth
Revenue change (TTM)
13.74%
Earnings per share change (TTM)
14.49%
3-year revenue growth (CAGR)
1.77%
10-year revenue growth (CAGR)
3.72%
3-year earnings per share growth (CAGR)
-5.83%
10-year earnings per share growth (CAGR)
5.72%
3-year dividend per share growth (CAGR)
6.61%
10-year dividend per share growth (CAGR)
7.92%
What the Analysts think about DGX
Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.
Bulls say / Bears say
Quest beat Q1 2025 consensus with revenue up 12.1% to $2.65 billion and adjusted EPS of $2.21, exceeding the FactSet estimate of $2.15, and reaffirmed full-year guidance (Reuters)
Q2 2025 revenues jumped 15.2% year-over-year to $2.76 billion with adjusted EPS rising 11.5% to $2.62, prompting management to raise full-year revenue and EPS outlook (RTTNews)
Labcorp’s strong Q1 2025 outperformance and raised profit forecast underscore robust diagnostic testing demand industry-wide, benefiting major players like Quest Diagnostics (Reuters)
Q1 2025 organic requisition volume declined 0.9% year-over-year, indicating potential normalization in test demand after post-COVID highs (Quest Diagnostics Q1 2025 Results)
Quest faces a projected $100 million annual hit starting in 2026 from the Protecting Access to Medicare Act’s planned 15% cuts to Medicare Clinical Laboratory Fee Schedule rates (Investors Business Daily)
Tariff-related costs, while manageable, are expected to persist through Q3 and Q4 2025, pressuring margins as import duties on lab supplies remain in effect (Webull)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
DGX Financial Performance
Revenues and expenses
DGX Earnings Performance
Company profitability
DGX News
AllArticlesVideos
Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings
Benzinga2 days ago
Quest Diagnostics raises annual profit and revenue forecasts on lab test demand
Reuters4 days ago
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Quest Diagnostics stock?
Quest Diagnostics (DGX) has a market cap of $20B as of October 24, 2025.
What is the P/E ratio for Quest Diagnostics stock?
The price to earnings (P/E) ratio for Quest Diagnostics (DGX) stock is 21.52 as of October 24, 2025.
Does Quest Diagnostics stock pay dividends?
Yes, the Quest Diagnostics (DGX) stock pays dividends to shareholders. As of October 24, 2025, the dividend rate is $3.15 and the yield is 1.75%. Quest Diagnostics has a payout ratio of 35.81% on a trailing twelve-month basis.
When is the next Quest Diagnostics dividend payment date?
The next Quest Diagnostics (DGX) dividend payment date is unconfirmed.
What is the beta indicator for Quest Diagnostics?
Quest Diagnostics (DGX) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.